The Medicare GLP-1 Bridge program launched on July 1, 2026, giving eligible Medicare Part D enrollees access to Wegovy, Zepbound, and the new oral GLP-1 pill Foundayo at a fixed $50 monthly copay. For many seniors who were previously paying more than $1,000 a month out of pocket, or going without treatment entirely, the program is a genuine breakthrough in access.
But the program has an expiration date. Coverage ends on December 31, 2027. The longer-term program originally designed to replace it — the BALANCE Model — has been delayed indefinitely by the Centers for Medicare and Medicaid Services. No permanent legislative fix to Medicare's statutory prohibition on covering weight-loss drugs has been passed by Congress. Seniors who pick up their first prescription this month are beginning an 18-month treatment course with no guaranteed path to affordable coverage when it ends.
Why This Matters
GLP-1 medications work only as long as patients take them. Clinical studies consistently show that most people who stop semaglutide or tirzepatide regain a substantial portion of the weight they lost — and research suggests the regained weight is disproportionately fat rather than the lean muscle mass that may have been lost during treatment. A senior who loses 15 to 20 percent of body weight over 18 months, improves blood pressure, reduces cardiovascular risk, and gains mobility — and then loses access to the drug — faces both health consequences and the prospect of paying list prices that currently exceed $1,000 per month.
As KFF noted in its policy analysis: "It is uncertain how participating beneficiaries will be able to maintain Medicare coverage of their GLP-1 medication for obesity after the Medicare GLP-1 Bridge ends at the end of 2027."
What We Know So Far
The Medicare GLP-1 Bridge is a federal demonstration program, not a Part D benefit. It operates outside the standard Part D framework through a contract with Humana as the central processor. Claims go through a separate BIN/PCN number, and the $50 copay does not count toward Part D deductibles or the annual out-of-pocket spending cap. Low-income subsidy programs including Extra Help cannot be applied to reduce the copay below $50.
An estimated 3.8 million Medicare beneficiaries are eligible under the program's current criteria, based on a KFF analysis of 2023 Part D enrollment data. To qualify, beneficiaries must be enrolled in an eligible Part D plan and have a BMI of 27 or higher with at least one qualifying comorbidity such as heart disease or prediabetes, or a BMI of 35 or higher regardless of comorbidities.
The BALANCE Model was originally designed to begin in January 2027 as the Bridge's successor, giving private Part D plans a framework to cover GLP-1 obesity drugs on a sustained basis. In April 2026, CMS confirmed that the required 80 percent threshold for Part D plan participation was not met, and the Medicare Part D portion of BALANCE will not launch in 2027. CMS extended the Bridge to December 31, 2027 to fill the gap, but what follows after that remains unresolved.
As the American Journal of Managed Care noted: "If Congress has not acted by the time the Bridge expires, patients who have been on these medications for a year and a half face an abrupt coverage cliff."
What Changed and Why It Matters Now
The program was announced months ago, but the funding-cliff question becomes practically urgent only when seniors are actively enrolling and taking their first doses — which is now. A senior who began Wegovy or Zepbound in July 2026 will reach peak metabolic benefit in late 2027, precisely as the program is set to expire. Understanding that timeline before starting treatment is different from reading about it in advance.
Juliette Cubanski, vice president and director of Medicare policy at KFF, put it plainly to CBS News: "In the short term, we have this temporary program, and then no clear path forward yet as to what will happen at the end of 2027." CMS Administrator Mehmet Oz framed the Bridge as a stopgap at launch, according to AJMC, but has not indicated when or whether a permanent mechanism will follow.
No congressional legislation permanently lifting Medicare's statutory prohibition on covering weight-loss drugs has been enacted. Expanded GLP-1 utilization is projected to cost up to $47.7 billion under a Medicare coverage model, a figure that has complicated legislative momentum.
Where the Access Gaps Are Greatest
Low-income seniors face the sharpest tension in the program as currently structured. The $50 monthly copay equals $600 per year — and for a senior whose income qualifies them for Extra Help because it falls near the federal poverty level, that represents meaningful out-of-pocket spending from a fixed budget. Unlike most Part D prescriptions, the $50 copay cannot be reduced through any discount program, manufacturer coupon, or low-income subsidy.
Seniors in high-density Medicare metro areas — Miami, Phoenix, Tampa, Las Vegas, Jacksonville, Houston, and others — are among the populations where eligible enrollment is expected to be highest and where the 2027 cliff could affect the largest number of people simultaneously.
Additionally, some seniors have already encountered prior authorization challenges and plan confusion in the program's first weeks, according to enrollment discussions on Medicare Rights Center's platform. Early reports indicate that some pharmacies have attempted to route Bridge claims through standard Part D plans, resulting in denials. Claims must be submitted to the Bridge's central processor to be adjudicated correctly.
What Doctors and Experts Say
Clinicians have raised a concern that goes beyond cost. As summarized by the American Journal of Managed Care: "Physicians have pointed out that no other chronic condition in Medicare is treated this way — with an effective medication offered temporarily and then potentially withdrawn."
For obesity, which is classified as a chronic condition by the American Medical Association and most major medical societies, offering 18 months of effective treatment with no guaranteed continuation is clinically unusual. The analogy from physicians is that this would be equivalent to providing blood pressure medication through 2027 and then asking patients to return to uncontrolled hypertension.
Pharmacists have also flagged operational issues. According to Pharmacy Times, early denials often reflect incorrect claim routing through patients' usual Part D plans rather than through the Bridge's designated central processor — a technical issue that requires prescriber documentation and pharmacy resubmission.
Who Faces the Greatest Risk?
Seniors who are most medically motivated to start GLP-1 therapy — those with severe obesity, established cardiovascular disease, or significant comorbidities — are precisely the people who stand to gain the most from sustained treatment and who face the greatest health risk from abrupt discontinuation at the end of 2027.
Seniors over 75 face the added concern that GLP-1 drugs carry specific risks in older bodies — including muscle loss and bone density reduction — that require ongoing clinical monitoring. Beginning an 18-month treatment course without a clear post-2027 plan means initiating that monitoring without knowing whether it will continue.
What You Can Do Now
Before beginning GLP-1 therapy under the Bridge program, seniors should ask their prescribing clinician two specific questions: What is the plan if coverage ends on December 31, 2027? And what will my out-of-pocket cost be if I need to continue this medication without insurance coverage?
Those are not pessimistic questions. They are the same questions a clinician would ask before starting any treatment with a defined end date. Drug manufacturers Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) have offered patient assistance programs in the past; eligibility criteria and availability should be confirmed directly with the manufacturer.
Seniors who do not qualify for the Bridge under current criteria — or who face prior authorization delays — can contact the Medicare Rights Center or their State Health Insurance Assistance Program (SHIP) for guidance. The SHIP program provides free counseling to Medicare beneficiaries in every state.
Cost and Access: What Patients Should Know
The $50 copay covers a 30-day supply of Wegovy injections or pills, Zepbound KwikPens, or Foundayo tablets. Zepbound single-use pens and vials are not included. Claims must be submitted to the Bridge's central processor — not to the enrollee's standard Part D plan — to be processed correctly.
Patients receiving prior authorization denials from their regular Part D insurer should confirm with their pharmacist and prescriber that the claim is being submitted through the correct Bridge pathway. The Medicare GLP-1 Bridge prior authorization request form is available through CMS and requires prescriber attestation of clinical eligibility criteria.
What Happens Next
The Medicare GLP-1 Bridge runs through December 31, 2027. CMS has given no public timeline for whether BALANCE will be relaunched for Medicare, whether a new demonstration will follow, or whether Congress will act on permanent coverage. CMS has indicated it intends to collect utilization data through the Bridge to inform future coverage decisions, but that data alone does not guarantee a successor program.
Semaglutide was selected for Medicare drug price negotiation in 2025, with a negotiated price set to take effect in 2027 — but that negotiated price applies to diabetes and cardiovascular indications covered under current Medicare statute, not to obesity, which remains statutorily excluded.
MedicalDaily will track legislative developments and any CMS announcements about coverage continuity beyond December 2027.
The Bottom Line
The Medicare GLP-1 Bridge program is a meaningful step toward access for millions of older Americans who could not previously afford these medications. But it is an 18-month bridge to an uncertain destination. Seniors beginning treatment now should understand that coverage expires December 31, 2027, that the successor program has been delayed indefinitely, and that no permanent coverage guarantee exists. Starting the conversation with a clinician about what happens next — before the first injection — is an important part of an informed decision.
